NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Bioventus Inc. (BVS) Stock Analysis

Bioventus Inc. (BVS) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

BVS

$14.07

−$0.29 (−2.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BVS with… →

BVS Key Statistics

As of Sep 4, 2026
Trading
Open
$14.11
Previous Close
$14.36
Day's Range
13.91–14.31
52-Week Range
6.26–15.89
Volume
502.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.65
Valuation
Market Cap
$961.05M
P/E Ratio
18.51
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.29
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.56
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.65
EPS (ttm)Profit attributable to each share over the last twelve months.
0.76
Financials (FY)
Revenue (FY)
$568.09M−0.91%
Net Income (FY)
$22.73M
Profit marginThe share of revenue left as profit after all costs and taxes.
9.36%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.31M
1-Year Return
+98.17%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
710.41K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BVS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+89.11%
2025−29.14%
2024+99.24%
2023+101.92%
2022−81.99%
2021 (partial year)−24.57%

As of September 4, 2026.

BVS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$568.09M$22.73M4.0%
2024$573.28M−$36.13M−6.3%
2023$512.35M−$156.23M−30.5%
2022$512.12M−$158.70M−31.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$568.09M$388.16M$56.29M$22.73M4.0%
2024$573.28M$388.23M$22.83M−$36.13M−6.3%
2023$512.35M$328.19M$2.03M−$156.23M−30.5%
2022$512.12M$331.08M−$34.66M−$158.70M−31.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BVS Valuation vs Medical Devices Median

Median of 151 stocks
MetricBVSMedical Devices medianvs median
P/E18.5126.8031% below
P/S ratio1.652.9844% below
Profit margin9.36%−1.69%11.1 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bioventus Inc. (BVS) carries a market capitalisation of $961.05M. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 950.

Over the past 52 weeks the price has ranged from $6.26 to $15.89. BVS last closed at $14.07 on September 4, 2026. That is −$0.29 (−2.02%) against the previous close. The latest close sits 124.94% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $568.09M. Against the prior fiscal year total of $573.28M, that is a change of −0.91%. The same year closed with net income of $22.73M. The reported profit margin is 9.36%. That is 11.1 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are 0.76.

Across the 4 fiscal years on file, revenue moves from $512.12M in 2022 to $568.09M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

BVS trades at a trailing price-to-earnings ratio of 18.51. That is 30.93% below the Medical Devices median of 26.8. On forward earnings the ratio is 15.29. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.56. The price-to-sales ratio is 1.65. On price-to-sales that is 44.5% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 0.65. Annualized volatility over the trailing 5 years is 81.47%. The trailing one-year price return is +98.17%. Measured over 5 years, that is −1.29% a year compounded.

Growth & Income

No dividend is on file for BVS.

So far in 2026 the price is +89.11%. Across the complete calendar years on file, 2023 returned +101.92% and 2022 returned −81.99%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Bioventus Inc. (BVS) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bioventus Inc. BVS $961.05M 18.5
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Bioventus Inc. trades at a P/E of 18.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Visit website →